<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs) and other <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>) are rare entities, particularly in children </plain></SENT>
<SENT sid="1" pm="."><plain>The latest classification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e> separates them into 3 major groups: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e>-associated myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>.Although the blast count plays a central role in differentiating <z:hpo ids='HP_0001909'>leukemias</z:hpo> from MDSs, it is by no means sacrosanct; biological features as well as disease characteristics are also important considerations for diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>Genetic alterations in MDSs have increasingly been noted in a majority of patients and when detected make diagnosis easy </plain></SENT>
<SENT sid="3" pm="."><plain>Hematopoietic stem cell transplant is the treatment of choice, while newer agents have shown promise in adults and are presently in the advanced stages of clinical trials </plain></SENT>
</text></document>